A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevac… (NCT07619235) | Clinical Trial Compass
Not Yet RecruitingPhase 4
A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer
32 participantsStarted 2026-07-01
Plain-language summary
This is a single-arm, multicenter clinical study designed to evaluate the efficacy and safety of Iparomlimab and Toripalimab (QL1706) in combination with bevacizumab and chemotherapy as first-line treatment for patients with advanced biliary tract cancer
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. Cardiac insufficiency classified as Class II or higher according to the New York Heart Association (NYHA) criteria, or Left Ventricular Ejection Fraction (LVEF) \< 50% on echocardiography;
. Unstable angina pectoris;
. Myocardial infarction within 1 year prior to study entry;
. Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;
. QTc interval \> 450 ms (male) or \> 470 ms (female) (QTc calculated using the Fridericia formula; if abnormal, repeat ECG three times at 2-minute intervals and use the average value).
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial combines four different treatments — iparomlimab, toripalimab, bevacizumab, and chemotherapy — all at once as a first-line approach; given how intensive that regimen sounds, what kinds of side effects should I realistically expect, and how does the safety profile compare to what's already established for biliary tract cancer treatment?
2Since this is a Phase 4 trial, does that mean these drugs have already been approved and this study is mainly looking at how well they work together in broader use, and what does that mean for how much is already known about their safety versus a Phase 1 or 2 study?
3The trial hasn't started recruiting yet — do you know roughly when it might open, and given my diagnosis is now, would waiting for it to begin put me at a disadvantage compared to starting standard treatment right away?
4The main thing this trial is measuring is whether patients are progression-free at six months — is that a meaningful milestone for my specific situation, and what happens to participants after that point in terms of ongoing monitoring and care?
5Since this is a single-arm study with no comparison group, how will my doctor and I actually know whether this combination is working better than what I might receive outside of a trial, and is there a standard of care option we should consider first?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.